Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn’s Disease Patients

Shen, Meiqin; Shi, Yingqi; Ge, Zhenming; Qian, Junbo

doi:10.1080/08941939.2023.2297565

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mesalazine is the aminosalicylate most commonly prescribed to patients with ulcerative colitis (UC) or Crohn’s disease for the maintenance of remission and in association with corticosteroids for the induction of remission in mild-moderate active forms. The incidence of mesalazine-associated hepatotoxicity remains low because mesalazine is minimally absorbed and mostly eliminated in the feces [ 23 , 24 ]. Adverse hepatic effects associated with mesalazine range from a mild asymptomatic increase in hepatic cytolysis rates to idiosyncratic cholestasis, and in most cases, these events resolve rapidly with discontinuation of the drug [ 25 ].…”

Section: Aminosalicylatesmentioning

confidence: 99%

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Catanzaro,

Marotta,

Yazdani

et al. 2024

Toxics

View full text Add to dashboard Cite

Drug-induced liver disease (DILI) represents one of the main problems in the therapeutic field. There are several non-modifiable risk factors, such as age and sex, and all drugs can cause hepatotoxicity of varying degrees, including those for the treatment of inflammatory bowel diseases (IBD). The aim of this review is to illustrate the adverse effects on the liver of the various drugs used in the treatment of IBD, highlighting which drugs are safest to use based on current knowledge. The mechanism by which drugs cause hepatotoxicity is not fully understood. A possible cause is represented by the formation of toxic metabolites, which in some patients may be increased due to alterations in the enzymatic apparatus involved in drug metabolism. Various studies have shown that the drugs that can most frequently cause hepatotoxicity are immunosuppressants, while mesalazine and biological drugs are, for the most part, less associated with such complications. Therefore, it is possible to assume that in the future, biological therapies could become the first line for the treatment of IBD.

show abstract

Section: Aminosalicylatesmentioning

confidence: 99%

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Catanzaro,

Marotta,

Yazdani

et al. 2024

Toxics

View full text Add to dashboard Cite

show abstract

Anthocyanins-rich cranberry extract attenuates DSS-induced IBD in an intestinal flora independent manner

Wang,

Yuan,

Wang

et al. 2024

Current Research in Food Science

View full text Add to dashboard Cite

From gut to brain: understanding the role of microbiota in inflammatory bowel disease

Wang,

Zhou,

Han

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

With the proposal of the “biological-psychological-social” model, clinical decision-makers and researchers have paid more attention to the bidirectional interactive effects between psychological factors and diseases. The brain-gut-microbiota axis, as an important pathway for communication between the brain and the gut, plays an important role in the occurrence and development of inflammatory bowel disease. This article reviews the mechanism by which psychological disorders mediate inflammatory bowel disease by affecting the brain-gut-microbiota axis. Research progress on inflammatory bowel disease causing “comorbidities of mind and body” through the microbiota-gut-brain axis is also described. In addition, to meet the needs of individualized treatment, this article describes some nontraditional and easily overlooked treatment strategies that have led to new ideas for “psychosomatic treatment”.

show abstract

Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn’s Disease Patients

Cited by 3 publications

References 20 publications

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Anthocyanins-rich cranberry extract attenuates DSS-induced IBD in an intestinal flora independent manner

From gut to brain: understanding the role of microbiota in inflammatory bowel disease

Contact Info

Product

Resources

About